Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules.
|
28079144 |
2017 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Subgroup analyses by menopausal status, invasiveness, or estrogen receptor status of breast cancer did not reveal evidence of association between telomere length in blood cells and subsequent breast cancer risk.
|
21643930 |
2011 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
A large proportion of breast cancers expresses the estrogen receptor alpha (ERα) and are dependent on estrogens for their proliferation and survival.
|
20221692 |
2011 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The adenoviral assay enabled ER activity to be readily determined in purified cells from primary breast cancers and secondary sites.
|
14566818 |
2003 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
70% of all breast cancer cases are estrogen receptor (ER)-positive and express ERα.
|
22787161 |
2012 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
With the advent of omic technologies, our understanding of the molecular mechanisms underlying estrogen receptor α (ERα)-expressing breast cancer (BC) progression has grown exponentially.
|
30389467 |
2019 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry using the antibodies p63, CK5 and p-cadherin, and also estrogen receptor (ER) and Human Epidermal Receptor Growth Factor 2 (HER2), was per-formed on 168 samples from a breast cancer case series.
|
17992394 |
2007 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The expression of estrogen receptor is the key in most breast cancers (BC) and binding of estrogen receptor to the genome correlates to Forkhead protein (FOXA1) expression.
|
26708273 |
2016 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Comparison of variant expression of estrogen receptor mRNA in normal breast tissue and breast cancer.
|
9538123 |
1998 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The positive association of postmenopausal BC risk and specifically estrogen receptor (ER)-positive BC, is presumably due largely to accumulation of estrogen in the adipose tissue of the breast and other tissues.
|
31555578 |
2019 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Patients with estrogen receptor α (ERα)-positive breast cancer can benefit from long-term hormonal treatment.
|
24520076 |
2014 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
One-third of all breast cancers lack ER and PR; these conditions are associated with less differentiated tumors and poorer clinical outcome.
|
10819507 |
1998 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
A panel of ER<sup>+</sup> BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1 <sup>wt</sup> or ESR1 <sup>Y537S</sup> , modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780).
|
29880014 |
2018 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that the observed expression of Skp2B in breast cancer does contribute to tumorigenesis at least in part by modulating the activity of the estrogen receptor.
|
17785450 |
2007 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
However, an understanding of the potential relationship between HOXA7 and ER in breast cancer cells is limited.
|
24099775 |
2013 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Because of the role of estrogens in promoting the growth and progression of breast cancer, there is great interest in exploring ways to functionally inactivate the ER, thereby suppressing ER-mediated gene expression and cell proliferation.
|
12943695 |
2003 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Epigenetic modulation of estrogen receptor-alpha by pRb family proteins: a novel mechanism in breast cancer.
|
17699777 |
2007 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In a large multiethnic case-control study, the G/A870 polymorphism conferred no significant risk for breast cancer overall or by stage or estrogen receptor (ER) status.
|
19287456 |
2009 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Expert opinion: The discovery of GPER-1 as a novel estrogen receptor is unique and the signaling pathways activated by its stimulation, when compared to the classical nuclear ERα, indicate a potential role of GPER-1 in the genesis and mechanisms of drug resistance in breast cancer.
|
28671018 |
2017 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
These studies also provide evidence for combining TOB1 inhibition and AKT/mTOR inhibition as a therapeutic strategy, with potential translational significance for the management of patients with ER-positive breast cancers.
|
26165839 |
2016 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Connecting estrogen receptor function, transcriptional repression, and E-cadherin expression in breast cancer.
|
12726856 |
2003 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Collectively, the results indicate that FGF-8 acts to facilitate cell proliferation by upregulating endogenous estrogenic actions as well as by suppressing BMP receptor signaling in ER-expressing breast cancer cells.
|
21664418 |
2011 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-positive (ER<sup>+</sup>) breast cancer.
|
28270497 |
2017 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Estrogen receptor (ER) expression and proliferative activity are established prognostic factors in breast cancer.
|
18593943 |
2008 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the anti-proliferative and cytotoxic effects of CCT137690 on estrogen receptor (ER)-positive human breast cancer cell line (MCF-7) and ER-negative human breast cancer cell line (MDA-MB-231).
|
31319040 |
2020 |